MASCC Guidelines and Assessment Tools
©MASCC, Multinational Association for Supportive Care in Cancer™ • All rights reserved worldwide.
The MASCC/ESMO Antiemetic Guidelines have been updated in English as of January 2013. The guidelines are available in ten languages, obtained by the standard forward/backward translation process.
On behalf of the ESMO/MASCC Guidelines Working Group, the updated antiemetic guidelines have been published in the Annals of Oncology. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. F. Roila, J. Herrstedt, M. Aapro, R.J. Gralla, et al. , Annals of Oncology 21 (Supplement 5): v232 - v243, 2010
A major effort of the Mucositis Study Group of MASCC/ISOO has been a comprehensive review of the literature related to mucositis and the development of evidence-based clinical practice guidelines. The first set of MASCC/ISOO Mucositis Guidelines were published in the journal Cancer in 2004. The first update of these guidelines was described in publications in 2006-2007. These included a paper summarizing the guidelines published in the journal Cancer, and a set of papers, published in Supportive Care in Cancer, that reported the detailed results for the various categories of interventions. A summary of the most recent update of the MASCC/ISOO Mucositis Guidelines is now available on this website. In addition, a set of papers has been published in Supportive Care in Cancer in 2013, that describes detailed results for different categories of interventions for mucositis.
MASCC Endorsed Guideline Partnerships
Acute AINV Guideline
From the Pediatric Oncology Group of Ontario (POGO)
Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients
The purpose of this guideline is to provide health care providers with an approach to the prevention of acute antineoplastic-induced nausea and vomiting (AINV) in children who are receiving antineoplastic medication. The scope is limited to the prevention of AINV in the acute phase (within 24 hours of administration of an antineoplastic agent). >> MORE
For more information contact:
Åge Schultz, DVM, PhD - MASCC Executive Director
Herredsvejen 2, DK-3400 Hillerød Denmark
Phone: +45 4820 7022; Fax: +45 4821 7022
MASCC Antiemesis Tool© (MAT)
The MASCC Antiemesis Tool© (MAT) was first created and posted in 2004. It is now available in several languages,obtained by the standard forward/backward translation process. The MAT is now validated, see Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L,Rittenberg C, Gralla RJ. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool. J Pain Symptom Manage. 2007 Aug; 34(2): 148-159. The MASCC Antiemesis Tool© (MAT) was developed by members of MASCC to assist patients and oncology professionals in communicating accurately about the prevention and control of nausea and vomiting that may occur with chemotherapy. The concept of the MAT is to provide an easy-to-use and easy-to-evaluate tool to assist in providing the best individual care to patients. Additionally, the tool will aid treatment centers in understanding the effectiveness of their antiemetic strategies. Available in print and an iPhone/iPad app to assist you in assessing your patient's chemotherapy.
MASCC Oral Agent Teaching Tool© (MOATT)
The MASCC Oral Agent Teaching Tool© (MOATT) was developed by the MASCC Education Study Group to meet an identified need for health care providers involved in education of patients receiving oral anticancer agents to provide comprehensive, standardized instruction. The MOATT provides a structured format to ensure all key areas of patient assessment and teaching are addressed. It allows for individualization of teaching and uses evidence-based tenets in pt education. The MOATT has been recognized as a useful tool – cited in articles, used in research and quality improvement projects, and as an easy assist in patient education. The MOATT is easy-to-use, well researched and refined. Available in several languages that were translated using the standard forward/backward translation process.
MASCC EGFR Inhibitor Skin Toxicity Tool© (MESTT)
The MASCC EGFR Inhibitor Skin Toxicity Tool© (MESTT) was developed by the MASCC Skin Toxicity Study Group in 2008 as a tool to assist oncology health professions with the monitoring and reporting of dermatologic AEs in EGFRI-treated patients. The MESTT is an event-specific grading system that can be used to standardize assessment, optimize the use of EGFR inhibitors and enable researchers to conduct more informative, controlled studies in this patient population.